Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies

[1] Odorico JS(1995)Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection Lancet 345 1321-1325

[2] Pirsch JD(1996)A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation Transplantation 61 1029-1037

[3] Knechtle SJ(1998)A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation Transplantation 66 1751-1759

[4] D’Alessandro AM(2003)Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies Am J Transplant 3 534-542

[5] Sollinger HW(1995)Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal transplant mycophenolate mofetil study group Transplantation 60 225-232

[6] Shaw LM(2001)A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients Liver Transpl 7 442-450

[7] Korecka M(1993)The design and development of an immunosuppressive drug, mycophenolate mofetil Springer Semin Immunopathol 14 353-380

[8] Venkataramanan R(1995)Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics Clin Chem 41 1011-1017

[9] Goldberg L(1998)Clinical pharmacokinetics of mycophenolate mofetil Clin Pharmacokinet 34 429-455

[10] Bloom R(1999)Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite Transplant Proc 31 1135-1137

[1] Odorico JS(1995)Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection Lancet 345 1321-1325

[2] Pirsch JD(1996)A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation Transplantation 61 1029-1037

[3] Knechtle SJ(1998)A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation Transplantation 66 1751-1759

[4] D’Alessandro AM(2003)Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies Am J Transplant 3 534-542

[5] Sollinger HW(1995)Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal transplant mycophenolate mofetil study group Transplantation 60 225-232

[6] Shaw LM(2001)A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients Liver Transpl 7 442-450

[7] Korecka M(1993)The design and development of an immunosuppressive drug, mycophenolate mofetil Springer Semin Immunopathol 14 353-380

[8] Venkataramanan R(1995)Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics Clin Chem 41 1011-1017

[9] Goldberg L(1998)Clinical pharmacokinetics of mycophenolate mofetil Clin Pharmacokinet 34 429-455

[10] Bloom R(1999)Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite Transplant Proc 31 1135-1137